The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

Raltegravir (MK-0518) is the first integrase (IN) inhibitor to be approved by the US FDA and is currently used in clinical treatment of viruses resistant to other antiretroviral compounds. Virological failure of Raltegravir treatment is associated with mutations in the IN gene following two main dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Delelis, Olivier, Malet, Isabelle, Na, Li, Tchertanov, Luba, Calvez, Vincent, Marcelin, Anne-Genevieve, Subra, Frederic, Deprez, Eric, Mouscadet, Jean-François
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Nucleic Acid Enzymes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651800/
https://www.ncbi.nlm.nih.gov/pubmed/19129221
http://dx.doi.org/10.1093/nar/gkn1050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651800/
https://www.ncbi.nlm.nih.gov/pubmed/19129221
http://dx.doi.org/10.1093/nar/gkn1050

Ejemplares similares